Skip to main
VSTM

Verastem (VSTM) Stock Forecast & Price Target

Verastem (VSTM) Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 71%
Buy 29%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Verastem Inc. has demonstrated promising early efficacy with its drug combination of avutometinib and defactinib, particularly in low-grade serous ovarian carcinoma (LGSOC), which may establish a new standard of care for approximately 1,000 to 2,000 new patients annually. The company reported an overall response rate (ORR) of 68.8% and a disease control rate (DCR) of 93.8% in non-small cell lung cancer (NSCLC) patients treated at the recommended Phase 2 dose, indicating strong overall therapeutic potential. Additionally, the anticipated enhancement of tolerability through improved dosing strategies and supportive care measures further supports a positive outlook on Verastem's pipeline and potential market position.

Bears say

Verastem Inc. faces a negative outlook due to the observed lower overall response rates (ORR) in its treatment candidate for KRAS G12D mutations, compared to competitive therapies, indicating potential efficacy challenges in key cancer markets such as pancreatic cancer and non-small cell lung cancer (NSCLC). Additionally, the recent protocol changes in Phase 3 trials, which allow for dose reductions due to high-grade CPK elevations, could lead to even poorer patient prognoses and lower response rates than previously encountered in other KRAS mutation contexts. Furthermore, the toxicity issues associated with MEK inhibitors may result in significant patient dropouts during studies, further undermining the potential for successful outcomes in Verastem's developmental pipeline.

Verastem (VSTM) has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 71% of analysts recommend a Strong Buy, 29% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Verastem and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Verastem (VSTM) Forecast

Analysts have given Verastem (VSTM) a Strong Buy based on their latest research and market trends.

According to 7 analysts, Verastem (VSTM) has a Strong Buy consensus rating as of Jan 30, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13.29, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13.29, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Verastem (VSTM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.